Publications

Beltran H, Prandi D, Mosquera JMiguel, Benelli M, Puca L, Cyrta J, Marotz C, Giannopoulou E, Chakravarthi BVSK, Varambally S et al..  2016.  Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.. Nat Med. 22(3):298-305.

Beltran H, Prandi D, Mosquera JMiguel, Benelli M, Puca L, Cyrta J, Marotz C, Giannopoulou E, Chakravarthi BVSK, Varambally S et al..  2016.  Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.. Nat Med. 22(3):298-305.

Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R et al..  2016.  Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med.

Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R et al..  2016.  Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med.

Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R et al..  2016.  Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med.

Ceder Y, Bjartell A, Culig Z, Rubin MA, Tomlins S, Visakorpi T.  2016.  The Molecular Evolution of Castration-resistant Prostate Cancer. European Urology Focus.

Beltran H, Danila D, B M, Szmulewitz R., Vaishampayan U, Armstrong A., Stein M., Hoimes C, Pinski J., Scher H. et al..  2016.  A phase 2 study of the aurora kinase A inhibitor alisertib for patients with neuroendocrine prostate cancer (NEPC).

Robinson D, Van Allen EM, Wu Y-M, Schultz N, Lonigro RJ, Mosquera J-M, Montgomery B, Taplin M-E, Pritchard CC, Attard G et al..  2015.  Integrative clinical genomics of advanced prostate cancer.. Cell. 161(5):1215-28.

Robinson D, Van Allen EM, Wu Y-M, Schultz N, Lonigro RJ, Mosquera J-M, Montgomery B, Taplin M-E, Pritchard CC, Attard G et al..  2015.  Integrative clinical genomics of advanced prostate cancer.. Cell. 161(5):1215-28.

Robinson D, Van Allen EM, Wu Y-M, Schultz N, Lonigro RJ, Mosquera J-M, Montgomery B, Taplin M-E, Pritchard CC, Attard G et al..  2015.  Integrative clinical genomics of advanced prostate cancer.. Cell. 161(5):1215-28.

Mosquera J-M, Varma S, Pauli C, MacDonald TY, Yashinskie JJ, Varga Z, Sboner A, Moch H, Rubin MA, Shin SJ.  2015.  MAGI3-AKT3 fusion in breast cancer amended.. Nature. 520(7547):E11-2.

Mosquera J-M, Varma S, Pauli C, MacDonald TY, Yashinskie JJ, Varga Z, Sboner A, Moch H, Rubin MA, Shin SJ.  2015.  MAGI3-AKT3 fusion in breast cancer amended.. Nature. 520(7547):E11-2.

Beltran H, Eng K, Mosquera JMiguel, Sigaras A, Romanel A, Rennert H, Kossai M, Pauli C, Faltas B, Fontugne J et al..  2015.  Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.. JAMA Oncol. 1(4):466-74.

Chakravarty D, Sboner A, Nair SS, Giannopoulou E, Li R, Hennig S, Mosquera JMiguel, Pauwels J, Park K, Kossai M et al..  2014.  The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer.. Nat Commun. 5:5383.

Baca SC, Prandi D, Lawrence MS, Mosquera JMiguel, Romanel A, Drier Y, Park K, Kitabayashi N, MacDonald TY, Ghandi M et al..  2013.  Punctuated evolution of prostate cancer genomes.. Cell. 153(3):666-77.

Baca SC, Prandi D, Lawrence MS, Mosquera JMiguel, Romanel A, Drier Y, Park K, Kitabayashi N, MacDonald TY, Ghandi M et al..  2013.  Punctuated evolution of prostate cancer genomes.. Cell. 153(3):666-77.

Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat J-P, White TA, Stojanov P, Van Allen E, Stransky N et al..  2012.  Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.. Nat Genet. 44(6):685-9.

Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat J-P, White TA, Stojanov P, Van Allen E, Stransky N et al..  2012.  Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.. Nat Genet. 44(6):685-9.

Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat J-P, White TA, Stojanov P, Van Allen E, Stransky N et al..  2012.  Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.. Nat Genet. 44(6):685-9.

Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, Sboner A, Esgueva R, Pflueger D, Sougnez C et al..  2011.  The genomic complexity of primary human prostate cancer.. Nature. 470(7333):214-20.

Park K, Tomlins SA, Mudaliar KM, Chiu Y-L, Esgueva R, Mehra R, Suleman K, Varambally S, Brenner JC, MacDonald T et al..  2010.  Antibody-based detection of ERG rearrangement-positive prostate cancer.. Neoplasia. 12(7):590-8.

Rickman DS, Chen Y-B, Banerjee S, Pan Y, Yu J, Vuong T, Perner S, Lafargue CJ, Mertz KD, Setlur SR et al..  2010.  ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression.. Neoplasia. 12(12):1031-40.

Sboner A, Demichelis F, Calza S, Pawitan Y, Setlur SR, Hoshida Y, Perner S, Adami H-O, Fall K, Mucci LA et al..  2010.  Molecular sampling of prostate cancer: a dilemma for predicting disease progression.. BMC Med Genomics. 3:8.

Hofer MD, Kuefer R, Maier C, Herkommer K, Perner S, Demichelis F, Paiss T, Vogel W, Rubin MA, Hoegel J.  2009.  Genome-wide linkage analysis of TMPRSS2-ERG fusion in familial prostate cancer.. Cancer Res. 69(2):640-6.

Rickman DS, Pflueger D, Moss B, VanDoren VE, Chen CX, de la Taille A, Kuefer R, Tewari AK, Setlur SR, Demichelis F et al..  2009.  SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer.. Cancer Res. 69(7):2734-8.